Abstract:Immune dysregulation has been identified as a critical cause of the most common types of cardiovascular diseases (CVDs). Notably, the innate and adaptive immune responses under physiological conditions are typically regulated with high sensitivity to avoid the exacerbation of inflammation, but any dysregulation can probably be associated with CVDs. In this respect, progranulin (PGRN) serves as one of the main components of the regulation of inflammatory processes, which significantly contributes to the immunopathogenesis of such disorders. PGRN has been introduced among the secreted growth factors as one related to wound healing, inflammation, and human embryonic development, as well as a wide variety of autoimmune diseases. The relationship between the serum PGRN and TNF-α ratio with the spontaneous bacterial peritonitis constitute one of the independent predictors of these conditions. The full-length PGRN can thus effectively reduce the calcification of valve interstitial cells, and the granulin precursor (GRN), among the degradation products of PGRN, can be beneficial. Moreover, it was observed that, PGRN protects the heart against ischemia-reperfusion injury. Above all, PGRN also provides protection in the initial phase following myocardial ischemia-reperfusion injury. The protective impact of PGRN on this may be associated with the early activation of the PI3K/Akt signaling pathway. PGRN also acts as a protective factor in hyperhomocysteinemia, probably by down-regulating the wingless-related integration site Wnt/β-catenin signaling pathway. Many studies have further demonstrated that SARS-CoV-2 (COVID-19) has dramatically increased the risks of CVDs due to inflammation, so PGRN has drawn much more attention among scholars. Lysosomes play a pivotal role in the inflammation process, and PGRN is one of the key regulators in their functioning, which contributes to the immunomodulatory mechanism in the pathogenesis of CVDs. Therefore, investigation of PGRN actions can help find new prospects in the treatment of CVDs. This review aims to summarize the role of PGRN in the immunopathogenesis of CVD, with an emphasis on its treatment.

Progranulin in Regulation Mechanism of Glycolipid Metabolism and Renal Disease

Progranulin Induces Adipose Insulin Resistance and Autophagic Imbalance Via TNFR1 in Mice.

PGRN Exerts Inflammatory Effects Via SIRT1-NF-κB in Adipose Insulin Resistance.

Progranulin: A promising biomarker and therapeutic target for fibrotic diseases

Pgrn Induces Impaired Insulin Sensitivity And Defective Autophagy In Hepatic Insulin Resistance

Circulating PGRN is significantly associated with systemic insulin sensitivity and autophagic activity in metabolic syndrome.

The Role of Pgrn in Alzheimer'S Disease

Progranulin Controls Sepsis Via C/EBPα-Regulated Il10 Transcription and Ubiquitin Ligase/Proteasome-Mediated Protein Degradation.

Progranulin is essential for bone homeostasis and immunology

Research progress of progranulin and related diseases of reproductive system

Progranulin Protects Against Renal Ischemia/reperfusion Injury in Mice.

Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances

Progranulin Facilitates Conversion and Function of Regulatory T Cells under Inflammatory Conditions

Progranulin as a therapeutic target in neurodegenerative diseases

Therapeutic Potential of Progranulin in Hyperhomocysteinemia-Induced Cardiorenal Dysfunction.

Progranulin protects against renal ischemia|[sol]|reperfusion injury in mice

Progranulin Protects Against Endotoxin-Induced Acute Kidney Injury by Downregulating Renal Cell Death and Inflammatory Responses in Mice

Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases

Structure, Function, and Mechanism of Progranulin; the Brain and Beyond

Progranulin Ameliorates Lung Inflammation in an LPS-induced Acute Lung Injury Mouse Model by Modulating Macrophage Polarization and the MAPK Pathway

Progranulin promotes osteogenic differentiation of human periodontal ligament stem cells via tumor necrosis factor receptors to inhibit TNF‐α sensitized NF‐kB and activate ERK/JNK signaling